Givastomig data presented at ESMO 2024 and SITC 2024 highlights encouraging monotherapy data On track to dose first patient ...

Givastomig data presented at ESMO 2024 and SITC 2024 highlights encouraging monotherapy data On track to dose first patient in randomized Phase 2 study of uliledlimab ...

Expects to deliver three Investigational New Drug (IND) applications in next three years based on next-generation ADC technology -- Two new ...

A joint investigation by the French environmental group Bloom and the German consumer organisation Foodwatch has raised ...

A manufacturer-funded study found a significant decrease in annual total medical costs in patients with overweight/obesity ...

Monthly 140 mg erenumab injections are a safe and effective treatment for patients with nonopioid chronic migraine and medication overuse headaches.

A new BLA for datopotamab deruxtecan aims for FDA accelerated approval to treat EGFR-mutated NSCLC based on data from ...

Clinical development and trial testing of vesleteplirsen (SRP-5051) for Duchenne muscular dystrophy (DMD) was stopped, with ...

One woman’s journey from receiving her diagnosis to finding a treatment that helps manage her chronic skin condition.

Type 2 Diabetes, In Vivo Model, High-Voltage Electrotherapy, Glucose Tolerance Test (GTT), Hematological Analysis Kriman, V. (2024) Study of the Effect of High-Voltage Low-Frequency Electrotherapy on ...

Presented full dataset from first-in-human Phase 1a clinical trial demonstrating PMN310 was generally well-tolerated with ...

FDA End-of-Phase 2 Meeting Scheduled in Fourth Quarter2024 to Discussthe Design of aCM-101 Accelerated Approval Phase 3Trial in Primary ...